Clinical trials: Antibody-Mediated Rejection (AMR)
Antibody-mediated Rejection
Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR
Chronic-active antibody-mediated rejection (cAMR) due to de novo or pre-formed donor specific antibody (DSA) is currently considered the main cause of long-term allograft losses.Based on the aim of reducing or eliminating DSA…
- Trial name
- NCT03737136
- Testing
- Bortezomib
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Kidney Transplant Rejection, Antibody-mediated Rejection
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
This trial evaluates the addition of rituximab to standard of care in the treatment of antibody-mediated rejection in kidney transplant patients. The trial will involve adults and children.
- Trial name
- TAR:GET-1 (NCT03994783)
- Testing
- Rituximab, Methylprednisolone, Intravenous Immunoglobulin
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London